It's a great time to helm a large biotech company, generally. Big biotech players overall posted major growth last year, and their CEOs got richer in the process. Most got fat raises while others saw their bundles of pay pale in comparison to 2011 figures. We surveyed the total compensation packages of the 10 largest biotech companies based on market capitalization as of early May, sleuthing mostly proxy statements for the financial details on pay for some of the most powerful people in the industry. Check it out >>
They're not exactly carrying pitchforks and torches, but some activist shareholders are demanding satisfaction on executive pay.
Risk-management plans may be a burden for new drug launches, but they're proving to be a weapon against generic competition, too. As the New York Times reports, generics makers can't buy the supplies they need to knock off a product, thanks to REMS restrictions. So, they have to resort to asking branded drugmakers for supplies--and some of those companies aren't cooperating.
A duo of new earnings announcements from smaller drugmakers offers a microcosmic view of the Big Pharma results we've seen so far. Generic competition hurts, new drugs need to fill the gap--and a successful drug launch is a thing to behold.
The Swiss biotech scored positive efficacy data from a midstage trial with patients suffering from plaque psoriasis on its candidate ponesimod. And the company plans to follow up the results in planned late-stage trials.
United Therapeutics suffered a setback in its pursuit of commercializing an oral therapy for pulmonary arterial hypertension (PAH) yesterday, as the FDA rejected the company's new drug application with a dreaded complete response letter.
Bayer is on a roll. Just days after nabbing a speedy FDA approval of its cancer drug Stivarga (regorafenib), Bayer says it has nailed positive Phase III data on its new drug for rare cases of pulmonary arterial hypertension, which sets up an NDA that leave Bayer slugging it out with Actelion and Gilead for market share in 2014.
A published abstract ahead of a science meeting next week gave Actelion's investors a look at its late-stage data for macitentan, a key new therapy for pulmonary arterial hypertension it will depend on to replace its primary product on the market.
Sales of Actelion's top product, the blood pressure drug Tracleer, are faltering, so the Swiss company is planning to slash 135 jobs and refocus its R&D.
Now that Switzerland's Actelion believes it has the data necessary to win an approval for its successor to Tracleer, the Swiss biotech company is opting to shift gears, trimming up to 135 staffers as it refocuses on new therapies for rare diseases and specialty pharma.